Table 3

Univariate and multivariate analyses of overall survival (OS) in relation to immune-related adverse events (irAEs), low baseline erythrocyte sedimentation rate (ESR) values, type of chemotherapy, presence of allele A*01 and haplotype A*01 and/or A*02

OS
UnivariateMultivariate
Gender
(M vs F)
0.63 (0.36 to 1.12) p=0.12
Histology
(squamous vs non-squamous)
1.07 (0.66 to 1.74) p=0.79
Age
(≥68 vs <68 years)
1.11 (0.69 to 1.78) p=0.67
Radiotherapy
(yes vs no)
1.11 (0.69 to 1.77) p=0.67
TKI
(yes vs no)
0.92 (0.53 to 1.60) p=0.76
irAEs
(yes vs no)
0.49 (0.30 to 0.80) p=0.004*
NLR
(≥3 vs <3)
1.59 (0.96 to 2.63) p=0.07
CRP
(≥7 vs <7)
1.98 (1.08 to 3.64) p=0.03*
ESR
(≥39 vs <39)
1.81 (0.91 to 3.60) p=0.09
LDH
(≥400 vs <400)
0.76 (0.44 to 1.33) p=0.34
Type of chemotherapy
(Platinum-based vs other)
1.66 (1.02 to 2.72) p=0.04*
Heterozygosis locus A
(yes vs no)
6.78 (0.93 to 49.6) p=0.06*6.78 (0.93 to 49.6) p=0.06*
Heterozygosis locus DRB1
(yes vs no)
0.46 (0.21 to 0.99) p=0.05*
  • HR and its 95% CIs are reported. Data from human leukocyte antigen analysis are considered only if correlated with the endpoint of OS.

  • CRP, C-reactive protein; LDH, lactate dehydrogenase; NLR, neutrophil–lymphocyte ratio; TKI, tyrosine kinase inhibitor.